Apogee Therapeutics to be acquired by AbbVie for $135.11 per share in $10.9B deal
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
| Metric | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A |
| Gross Margin | 0.00% | 0.00% | 0.00% |
| Operating Expenses | $216.87M | $93.00M | $30.73M |
| Operating Income | $-216.87M | $-93.00M | $-30.73M |
| Operating Margin | 0.00% | 0.00% | 0.00% |
| Net Income | $-182.15M | $-83.98M | $-39.78M |
| Net Margin | 0.00% | 0.00% | 0.00% |
| EPS (Basic) | $-3.30 | $-1.66 | $-0.79 |
| EBITDA | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A |